Insulet has announced the FDA clearance of Omnipod GO, an insulin delivery device cleared for use for people with tTpe 2 diabetes age 18 or older who would typically take daily injections of long-acting insulin.
Omnipod GO is a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. It features a tubeless and waterproof Pod and seven different pre-programmed daily rates, ranging from 10 to 40 units per day, and operates without the need for a handheld device to control the Pod. It has been cleared for use with the following U-100 insulins: NovoLog, Fiasp, Humalog, Admelog, and Lyumjev.
The product was developed to serve people with Type 2 diabetes earlier in their treatment journey by starting them on Pod therapy for their insulin delivery, rather than daily injections. If a person becomes insulin-intensive, meaning they require both basal and bolus insulin, the transition to another Omnipod product would be seamless.
To read more, CLICK HERE.
